Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company. It was founded as a biotech startup in Osaka in December 2001, and traces its roots back to Osaka University. Kringle’s mission is to develop and commercialize innovative medicines for patients suffering from intractable diseases. Its current research and development focus is on the application of recombinant human hepatocyte growth factor (HGF) to treat patients with these rare diseases worldwide.